Finanzas de Atea Pharmaceuticals, Inc. (AVIR)AVIRAtea Pharmaceuticals, Inc.

Evaluating the bottom line, Atea Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.14%, provide a clear picture of how effectively AVIR converts its operational activities into shareholder value.

In the context of the broader market, AVIR competes directly with industry leaders such as EBS and TTRX. With a market capitalization of $324.03M, it holds a significant position in the sector. When comparing efficiency, AVIR's gross margin of N/A stands against EBS's 58.56% and TTRX's N/A. Such benchmarking helps identify whether Atea Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Atea Pharmaceuticals has reported consistent net income losses, with the latest figures showing a net income of -33,943,000 USD for Q2 2026. The forward P/E ratio is currently at 0, indicating no earnings expected in the near term, which is a concern for long-term investors.